<DOC>
	<DOC>NCT00861757</DOC>
	<brief_summary>This study is a randomized, double-blind, placebo and tamsulosin-controlled, parallel design, multinational study to evaluate the efficacy and safety of Tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign prostatic hyperplasia (BPH).</brief_summary>
	<brief_title>Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Signs and Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Asian males, with benign prostatic hyperplasia (BPH) for at least 6 months prior to initiation and IPSS score greater than or equal to 13 at the beginning of the treatment Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED) and overactive bladder (OAB) treatments at any time during the study. Have not taken Finasteride or Dutasteride therapy, Antiandrogenic hormone or any other BPH therapy, ED or OAB therapy for specified duration of time prior to the beginning of the treatment Prostate specific antigen (PSA) score beyond acceptable range defined for study at initiation History of urinary retention or lower urinary tract (bladder) stones within 6 months of initiation History of urinary urethral obstruction due to stricture, valves, sclerosis, or tumor at initiation Clinical evidence of prostate cancer at initiation Clinical evidence of any of the bladder or urinary tract conditions, which may affect lower urinary tract symptom at initiation History of cardiac conditions, including Angina requiring certain treatment with nitrates, unstable angina defined for study, positive cardiac stress test before starting the study History of significant central nervous system injuries (including stroke or spinal cord injury within 6 months of initiation) Use of any nitrates, cancer chemotherapy, androgens, antiandrogens, estrogens, luteinizing hormonereleasing hormone (LHRH)agonists/antagonists, or anabolic steroids at initiation</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>